Prof Stephane Oudard (Georges Pompidou Hospital, Paris, France) and Prof Noel Clarke (The Christie Hospital, Manchester, UK) discuss the implications of negative trial results with ecancertv at ASCO GU 2015 with special focus on the following abstracts:

COMET-1: Cabozantinib versus prednisone in metastatic castration-resistant prostate cancer patients previously treated with docetaxel and abiraterone and/or enzalutamide.

COMET-2 Final analysis of COMET-2: Cabozantinib versus mitoxantrone/prednisone in metastatic castration-resistant prostate cancer patients with moderate to severe pain who were previously treated with docetaxel and abiraterone and/or enzalutamide.

Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).